Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azintuxizumab vedotin
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Azintuxizumab vedotin is an investigational antibody-drug conjugate (ADC) developed by AbbVie for the treatment of multiple myeloma. It consists of a humanized and chimeric monoclonal IgG1-kappa antibody targeting SLAMF7 (also known as CS1, CD319), a cell-surface glycoprotein highly expressed on multiple myeloma cells, conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via a cathepsin B-cleavable peptide linker. The mechanism of action involves binding to SLAMF7 on malignant plasma cells, internalization of the ADC, and subsequent release of MMAE inside the cell, leading to microtubule disruption and apoptosis. Azintuxizumab vedotin has been studied in clinical trials for relapsed or refractory multiple myeloma but has not received regulatory approval[1][2][3][4][5][6][7].
- Other names
- azintuxizumab vedotinABBV-838ABBV838ABBV 838
02
Targets
SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on azintuxizumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azintuxizumab vedotin.